Drug intelligence / Profile preview

aSyn mAb

Development stage: Preclinical
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

aSyn mAb (CNS-shuttled) is a preclinical-stage monoclonal antibody being developed by Manifold Bio, in collaboration with Roche, for the treatment of Parkinson's disease and other rare synucleinopathies. The therapeutic is engineered using Manifold Bio's protein design platform to incorporate a blood-brain barrier (BBB) shuttle, which is intended to enhance the delivery of the antibody into the central nervous system. Once in the brain, the antibody is designed to bind to alpha-synuclein (aSyn), a protein that forms toxic aggregates in the brains of patients with Parkinson's disease, thereby facilitating its clearance or neutralization.

Other names: Alpha-synuclein monoclonal antibodyCNS-shuttled aSyn mAb

Targets

aggregated α-syn (Alpha-synuclein (α-syn))

Beyond the preview

Go deeper on aSyn mAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aSyn mAb.

Explore the full profile